Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Intesity Therapeutics Inc INTS

Healthcare Biotechnology
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.


NDAQ:INTS - Post by User

Intesity Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1384)
•••
  • IseneschalX
Comment by Iseneschalon Oct 31, 2025 8:14am
8 Views
Post# 36769366

RE:INTS....ur all being led to the Slaughter house

RE:INTS....ur all being led to the Slaughter house
Iseneschal wrote: $1.24 right now


Worth a repeat ?? Now trading at $0.98 on 50.5 million shares

It's going to get worse....drink some more Kool-Aide ; )

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities